Activating mutations of KRAS appear early in pancreatic cancer development and were shown to be induced by high glucose concentration, this discovery being instrumental in the better understanding of why diabetes support PDAC initiation [60]. This evidence concerns the gene KRAS and pancreatic neoplasm.